216 related articles for article (PubMed ID: 22882801)
1. Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.
Anand JP; Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
Chem Biol Drug Des; 2012 Nov; 80(5):763-70. PubMed ID: 22882801
[TBL] [Abstract][Full Text] [Related]
2. Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
Purington LC; Pogozheva ID; Traynor JR; Mosberg HI
J Med Chem; 2009 Dec; 52(23):7724-31. PubMed ID: 19788201
[TBL] [Abstract][Full Text] [Related]
3. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
[TBL] [Abstract][Full Text] [Related]
5. Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.
Purington LC; Sobczyk-Kojiro K; Pogozheva ID; Traynor JR; Mosberg HI
ACS Chem Biol; 2011 Dec; 6(12):1375-81. PubMed ID: 21958158
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
[TBL] [Abstract][Full Text] [Related]
7. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.
Margolis EB; Fujita W; Devi LA; Fields HL
Neuropharmacology; 2017 Sep; 123():420-432. PubMed ID: 28645621
[TBL] [Abstract][Full Text] [Related]
8. Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues.
Anand JP; Porter-Barrus VR; Waldschmidt HV; Yeomans L; Pogozheva ID; Traynor JR; Mosberg HI
Biopolymers; 2014 Jan; 102(1):107-14. PubMed ID: 24436042
[TBL] [Abstract][Full Text] [Related]
9. Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
Mosberg HI; Yeomans L; Harland AA; Bender AM; Sobczyk-Kojiro K; Anand JP; Clark MJ; Jutkiewicz EM; Traynor JR
J Med Chem; 2013 Mar; 56(5):2139-49. PubMed ID: 23419026
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
Neumeyer JL; Zhang B; Zhang T; Sromek AW; Knapp BI; Cohen DJ; Bidlack JM
J Med Chem; 2012 Apr; 55(8):3878-90. PubMed ID: 22439881
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activities.
Hu M; Giulianotti MA; McLaughlin JP; Shao J; Debevec G; Maida LE; Geer P; Cazares M; Misler J; Li L; Dooley C; Ganno ML; Eans SO; Mizrachi E; Santos RG; Yongye AB; Houghten RA; Yu Y
Eur J Med Chem; 2015 Mar; 92():270-81. PubMed ID: 25559207
[TBL] [Abstract][Full Text] [Related]
12. Benzylideneoxymorphone: A new lead for development of bifunctional mu/delta opioid receptor ligands.
Healy JR; Bezawada P; Griggs NW; Devereaux AL; Matsumoto RR; Traynor JR; Coop A; Cunningham CW
Bioorg Med Chem Lett; 2017 Feb; 27(3):666-669. PubMed ID: 28011222
[TBL] [Abstract][Full Text] [Related]
13. Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
Przydzial MJ; Pogozheva ID; Ho JC; Bosse KE; Sawyer E; Traynor JR; Mosberg HI
J Pept Res; 2005 Nov; 66(5):255-62. PubMed ID: 16218993
[TBL] [Abstract][Full Text] [Related]
14. Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
Piekielna J; De Marco R; Gentilucci L; Cerlesi MC; Calo' G; Tömböly C; Artali R; Janecka A
Biopolymers; 2016 May; 106(3):309-17. PubMed ID: 27038094
[TBL] [Abstract][Full Text] [Related]
15. Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth.
Sarkar DK; Sengupta A; Zhang C; Boyadjieva N; Murugan S
J Biol Chem; 2012 May; 287(20):16734-47. PubMed ID: 22451667
[TBL] [Abstract][Full Text] [Related]
16. Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.
Milan-Lobo L; Whistler JL
J Pharmacol Exp Ther; 2011 Jun; 337(3):868-75. PubMed ID: 21422164
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
18. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
Lei W; Vekariya RH; Ananthan S; Streicher JM
J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.
Giri AK; Apostol CR; Wang Y; Forte BL; Largent-Milnes TM; Davis P; Rankin D; Molnar G; Olson KM; Porreca F; Vanderah TW; Hruby VJ
J Med Chem; 2015 Nov; 58(21):8573-83. PubMed ID: 26465170
[TBL] [Abstract][Full Text] [Related]
20. Effects of N-Substitutions on the Tetrahydroquinoline (THQ) Core of Mixed-Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Ligands.
Harland AA; Bender AM; Griggs NW; Gao C; Anand JP; Pogozheva ID; Traynor JR; Jutkiewicz EM; Mosberg HI
J Med Chem; 2016 May; 59(10):4985-98. PubMed ID: 27148755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
